ERBB2 and breast carcinoma: As a result, investigations into the use of PAM pathway inhibitors have increasingly expanded to triple‐negative breast cancer and HER2‐positive breast cancer (Table 14) [71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81].